Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to 0.92.

  • Celldex Therapeutics' Equity Ratio fell 334.6% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year decrease of 334.6%. This contributed to the annual value of 0.94 for FY2024, which is 228.68% up from last year.
  • As of Q3 2025, Celldex Therapeutics' Equity Ratio stood at 0.92, which was down 334.6% from 0.95 recorded in Q2 2025.
  • Celldex Therapeutics' 5-year Equity Ratio high stood at 0.97 for Q1 2024, and its period low was 0.88 during Q3 2023.
  • Its 5-year average for Equity Ratio is 0.93, with a median of 0.94 in 2022.
  • As far as peak fluctuations go, Celldex Therapeutics' Equity Ratio soared by 1913.16% in 2021, and later plummeted by 589.87% in 2023.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Equity Ratio stood at 0.94 in 2021, then dropped by 1.97% to 0.92 in 2022, then dropped by 0.33% to 0.92 in 2023, then increased by 2.29% to 0.94 in 2024, then dropped by 2.12% to 0.92 in 2025.
  • Its Equity Ratio stands at 0.92 for Q3 2025, versus 0.95 for Q2 2025 and 0.95 for Q1 2025.